OncoSil Medical Limited (ASX:OSL)
Australia · Delayed Price · Currency is AUD 1.175
+0.025 (2.17%)
Aug 28, 2026, 3:48 PM AEST
OncoSil Medical Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 6.48 | 5.11 | 4.5 | 9.39 | 11.28 |
Cash & Short-Term Investments | 6.48 | 5.11 | 4.5 | 9.39 | 11.28 |
Cash Growth | 26.74% | 13.51% | -52.08% | -16.72% | -7.84% |
Accounts Receivable | 2.44 | 0.84 | 0.31 | 1.16 | 0.85 |
Other Receivables | - | 0.36 | 1.12 | 0.12 | 0.06 |
Receivables | 2.44 | 1.2 | 1.44 | 1.29 | 0.91 |
Inventory | 0.01 | - | - | - | - |
Prepaid Expenses | 0.46 | 0.41 | 0.39 | 0.44 | 0.47 |
Other Current Assets | - | - | - | 0.12 | 0.09 |
Total Current Assets | 9.38 | 6.72 | 6.33 | 11.23 | 12.74 |
Property, Plant & Equipment | 0.93 | 0.42 | 0.39 | 0.24 | 0.32 |
Total Assets | 10.31 | 7.15 | 6.72 | 11.47 | 13.07 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 5.2 | 1.92 | 1.12 | 0.96 | 0.93 |
Accrued Expenses | 0.1 | 0.43 | 0.34 | 0.16 | 0.34 |
Current Portion of Leases | 0.01 | 0.05 | 0.03 | 0.15 | 0.17 |
Other Current Liabilities | - | 1.63 | 0.45 | 0.3 | 0.33 |
Total Current Liabilities | 5.31 | 4.03 | 1.94 | 1.57 | 1.77 |
Long-Term Leases | - | 0.02 | 0.04 | 0.02 | 0.14 |
Other Long-Term Liabilities | 0.01 | - | - | - | - |
Total Liabilities | 5.31 | 4.04 | 1.98 | 1.59 | 1.91 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 105.46 | 96.43 | 90.09 | 86.51 | 79.91 |
Retained Earnings | -117.32 | -107.46 | -92.78 | -84.37 | -73.02 |
Comprehensive Income & Other | 16.86 | 14.14 | 7.42 | 7.74 | 4.28 |
Shareholders' Equity | 5 | 3.1 | 4.74 | 9.88 | 11.16 |
Total Liabilities & Equity | 10.31 | 7.15 | 6.72 | 11.47 | 13.07 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.01 | 0.07 | 0.07 | 0.17 | 0.3 |
Net Cash (Debt) | 6.46 | 5.04 | 4.43 | 9.22 | 10.98 |
Net Cash Growth | 28.20% | 13.75% | -51.96% | -15.97% | -6.63% |
Net Cash Per Share | 0.29 | 0.46 | 0.80 | 3.27 | 5.41 |
Filing Date Shares Outstanding | 26.73 | 14.22 | 8.33 | 4.94 | 2.48 |
Total Common Shares Outstanding | 26.73 | 14.22 | 8.33 | 4.94 | 2.48 |
Working Capital | 4.07 | 2.7 | 4.39 | 9.67 | 10.98 |
Book Value Per Share | 0.19 | 0.22 | 0.57 | 2.00 | 4.50 |
Tangible Book Value | 5 | 3.1 | 4.74 | 9.88 | 11.16 |
Tangible Book Value Per Share | 0.19 | 0.22 | 0.57 | 2.00 | 4.50 |
Machinery | - | 0.09 | 0.1 | 0.12 | - |
Construction In Progress | - | 0.34 | 0.33 | 0.06 | - |